Comparative assessment of three drug eluting stents with different platforms but with the same biodegradable polymer and the drug based on quantitative coronary angiography and optical coherence tomography at 12-month follow-up

Autor: Katarzyna Gil, Dariusz Dudek, Ricardo A. Costa, Tomasz Pawłowski, Robert J. Gil, Jacek Bil, Jacek Legutko
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Coronary angiography
Male
Time Factors
Polymers
medicine.medical_treatment
Coronary Artery Disease
030204 cardiovascular system & hematology
Coronary Angiography
0302 clinical medicine
Risk Factors
Absorbable Implants
030212 general & internal medicine
Cardiac imaging
medicine.diagnostic_test
Drug-Eluting Stents
Middle Aged
Stent strut thickness
Coronary Vessels
Treatment Outcome
Female
Radiology
Cardiology and Cardiovascular Medicine
Neointima proliferation
Tomography
Optical Coherence
medicine.drug
Month follow up
Neointima
medicine.medical_specialty
Prosthesis Design
03 medical and health sciences
Percutaneous Coronary Intervention
Optical coherence tomography
Predictive Value of Tests
medicine
Humans
Radiology
Nuclear Medicine and imaging
cardiovascular diseases
Aged
Cell Proliferation
Sirolimus
Original Paper
QCA
Hyperplasia
business.industry
Significant difference
Stent
Cardiovascular Agents
Stent strut cross-sectional area
OCT
business
Zdroj: The International Journal of Cardiovascular Imaging
ISSN: 1875-8312
1569-5794
Popis: The aim of this study was to compare neointima proliferation in three drug-eluting stents (DES) produced by the same company (Balton, Poland) which are covered with a biodegradable polymer and elute sirolimus (concentration: 1.0 and 1.2 µg/mm2), but have different stent platforms and strut thickness: stainless steel Prolim® (115 µm) and BiOSS LIM® (120 µm) and cobalt-chromium Alex® (70 µm). We analyzed data of patients with quantitative coronary angiography (QCA) and optical coherence tomography (OCT) at 12 months from BiOSS LIM Registry, Prolim Registry and Alex OCT clinical trial. There were 56 patients enrolled, in whom 29 Prolim® stents were deployed, in 11—BiOSS LIM® and in 16—Alex stents. The late lumen loss was the smallest in Prolim® subgroup (0.26 ± 0.17 mm) and did not differ from Alex® subgroup (0.28 ± 0.47 mm). This parameter was significantly bigger in BiOSS® subgroup (0.38 ± 0.19 mm; p
Databáze: OpenAIRE
Externí odkaz: